STOCK TITAN

Vera Therapeutics, Inc. - VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.

One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.

Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.

Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.

Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.

For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA), a biotechnology company focused on immunological diseases, announced that its CEO, Marshall Fordyce, will present at several investor conferences in November 2021. These include the Jefferies London Healthcare Conference (November 16-18) and the Evercore ISI HealthCONx (November 30 - December 2). Fordyce's presentations will discuss Vera’s lead product candidate, atacicept, aimed at treating autoimmune diseases. Replay links for all presentations will be available for 30 days on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
conferences
-
Rhea-AI Summary

Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
-
Rhea-AI Summary

The Phase 2a JANUS clinical trial for atacicept, conducted by Vera Therapeutics, demonstrated a significant and durable reduction in serum galactose-deficient IgA1 (Gd-IgA1) over 72 weeks in patients with IgA nephropathy (IgAN). The trial revealed that atacicept 75mg lowered serum Gd-IgA1 levels to the lowest risk quartiles, highlighting its potential to improve renal survival. These findings were presented at the American Society of Nephrology Kidney Week 2021. The company anticipates further results from the ongoing Phase 2b ORIGIN trial to clarify the implications of these reductions on renal function.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.96%
Tags
Rhea-AI Summary

Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences clinical trial
-
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA) will host a KOL webinar on IgA Nephropathy on September 20, 2021. The event will include presentations by experts Richard Lafayette, M.D., and Jonathan Barratt, Ph.D., focusing on the efficacy of atacicept in treating IgAN. Atacicept targets B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), with promising clinical trial data supporting its potential as a best-in-class therapy. The webinar will allow attendees to ask questions after the presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q2 2021 financial results, highlighting significant clinical and financial advancements. They initiated the Phase 2b clinical trial named 'ORIGIN' for atacicept in IgA nephropathy patients, aiming to establish it as the first disease-modifying therapy for this condition. The company reported a net loss of $3.4 million, with cash and equivalents totaling $91.6 million as of June 30, 2021, bolstered by IPO proceeds. The management team expanded with the appointment of Sean Grant as Chief Financial Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
Rhea-AI Summary

Vera Therapeutics announced the appointment of Sean Grant as Chief Financial Officer, effective immediately. With nearly 15 years in financial services, he brings expertise from CareDx and Citigroup, focusing on strategic investments and capital markets. CEO Marshall Fordyce emphasized Grant's significant experience will enhance the company's financial strategies as it develops its lead candidate atacicept, aimed at treating immunological diseases. Atacicept is expected to help patients with conditions like IgA nephropathy, addressing a market with no existing disease-modifying treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
management
-
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q1 2021 financial results and corporate updates on June 24, 2021. The company initiated the Phase 2b ORIGIN clinical trial for atacicept aimed at treating IgA nephropathy. Vera raised approximately $128 million in total over nine months, including $48.4 million from its public offering in May 2021. The net loss for Q1 was $4.7 million, with cash and equivalents at approximately $49.5 million as of March 31, 2021. Key personnel appointments were made to enhance clinical and operational capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
-
Rhea-AI Summary

Vera Therapeutics (NASDAQ: VERA), a biotechnology firm focused on serious immunological diseases, announced participation in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company's CEO, Marshall Fordyce, will present on June 4 at 9:00 AM PT (12:00 PM ET). A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days post-event. Vera's lead program, atacicept, targets IgA nephropathy and shows potential for other conditions like lupus nephritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
conferences
Rhea-AI Summary

Vera Therapeutics has priced its initial public offering (IPO) of 4,350,000 shares of Class A common stock at $11.00 per share, aiming to raise $47.85 million in gross proceeds. The offering is led by Jefferies, Cowen, and Evercore, with an option for underwriters to purchase an additional 652,500 shares. Trading on the Nasdaq under the ticker symbol VERA is expected to start on May 14, 2021, with the offering closing on May 18, 2021, pending customary conditions. Vera focuses on treatments for serious immunological diseases, notably developing atacicept for IgA nephropathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Vera Therapeutics (VERA)?

The current stock price of Vera Therapeutics (VERA) is $42.31 as of December 23, 2024.

What is the market cap of Vera Therapeutics (VERA)?

The market cap of Vera Therapeutics (VERA) is approximately 2.7B.

What is Vera Therapeutics?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

What is atacicept?

Atacicept is a fusion protein developed by Vera Therapeutics for the treatment of autoimmune diseases, administered as a subcutaneous injection once weekly.

What is the ORIGIN clinical trial?

The ORIGIN clinical trial is a series of studies evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN).

What is IgA nephropathy (IgAN)?

IgAN, also known as Berger’s disease, is a serious autoimmune disease of the kidney characterized by the production of immunogenic Gd-IgA1 and progressive kidney damage.

What is MAU868?

MAU868 is a monoclonal antibody developed by Vera Therapeutics to neutralize BK virus (BKV) infections, particularly in kidney transplant patients.

What recent achievements has Vera Therapeutics reported?

Vera recently announced positive 72-week data from its Phase 2b ORIGIN trial of atacicept in IgAN and received FDA Breakthrough Therapy Designation for atacicept.

How is atacicept administered?

Atacicept is administered as a subcutaneous injection once weekly.

What are the financial highlights of Vera Therapeutics?

For the quarter ended March 31, 2024, Vera reported a net loss of $28.4 million, with cash reserves to fund operations through the approval and U.S. launch of atacicept.

Who are Vera’s strategic partners?

Vera has various strategic partnerships and funding rounds to support its research and development, including J.P. Morgan, TD Cowen, and Evercore ISI.

Where can I find more information about Vera Therapeutics?

For more information, please visit the company's website at www.veratx.com.

Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.69B
58.22M
6.83%
95.11%
10.34%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE